🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/10/2020 17,15 17,42 16,79 17,17 +0,18% 3,67% 431.200
30/09/2020 17,34 17,97 16,91 17,14 -1,55% 6,11% 289.800
29/09/2020 17,46 18,08 17,25 17,41 -0,74% 4,75% 429.200
28/09/2020 17,93 17,93 17,05 17,54 -0,79% 4,91% 527.200
25/09/2020 17,46 17,80 17,12 17,68 +0,17% 3,89% 494.600
24/09/2020 17,47 18,06 16,82 17,65 -0,06% 7,10% 392.600
23/09/2020 18,65 18,95 17,64 17,66 -5,56% 7,02% 450.300
22/09/2020 19,21 19,21 18,27 18,70 -2,40% 4,92% 487.900
21/09/2020 21,55 21,55 19,00 19,16 -12,67% 11,83% 668.700
18/09/2020 22,42 22,88 21,24 21,94 -1,13% 7,31% 2.620.400
17/09/2020 21,50 22,29 21,02 22,19 +2,73% 5,91% 281.700
16/09/2020 21,21 22,03 21,21 21,60 +1,84% 3,87% 389.400
15/09/2020 23,32 23,32 21,03 21,21 -7,74% 9,82% 480.500
14/09/2020 22,94 23,89 22,84 22,99 +2,41% 4,58% 637.100
11/09/2020 23,11 23,49 22,35 22,45 -1,75% 4,93% 400.200
10/09/2020 23,47 23,71 22,70 22,85 +5,01% 4,28% 686.400
09/09/2020 21,10 22,06 21,10 21,76 +5,07% 4,55% 484.200
08/09/2020 20,52 21,35 20,17 20,71 -1,57% 5,75% 323.700
04/09/2020 21,00 21,20 19,81 21,04 +0,38% 6,62% 658.900
03/09/2020 22,44 22,71 20,95 20,96 -7,50% 7,84% 550.900
02/09/2020 22,81 22,96 22,31 22,66 -1,35% 2,83% 257.100
01/09/2020 23,72 24,15 22,79 22,97 -3,49% 5,75% 377.200
31/08/2020 22,60 24,35 22,21 23,80 +6,49% 9,47% 695.000
28/08/2020 22,64 23,27 22,01 22,35 -1,19% 5,57% 508.200
27/08/2020 23,65 23,75 22,36 22,62 -4,36% 5,88% 402.100
26/08/2020 24,02 24,17 23,45 23,65 -1,74% 3,00% 288.600
25/08/2020 22,63 24,14 21,98 24,07 +5,29% 9,54% 454.500
24/08/2020 25,13 25,24 22,81 22,86 -7,00% 9,67% 609.400
21/08/2020 24,64 24,80 24,16 24,58 -0,97% 2,60% 1.080.400
20/08/2020 25,00 25,17 24,49 24,82 -1,35% 2,72% 674.400